Keyphrases
Clinical High Risk
100%
Lung Cancer
100%
Surgical Intervention
100%
Stereotactic Body Radiation Therapy
100%
Decision Analysis
100%
Cost-effectiveness
37%
Overall Survival
25%
Median Survival
25%
Clinical Stage I
25%
Propensity Score Matching
25%
Stage I Lung Cancer
25%
Incremental Cost-effectiveness Ratio
25%
Expected Survival
25%
Hazard Ratio
12%
Prospective Randomized Trial
12%
Medicare
12%
Non-small Cell Lung Cancer (NSCLC)
12%
Aging Effect
12%
Remaining Lifetime
12%
Early-stage Lung Cancer
12%
Confounding Effect
12%
Cause-specific Survival
12%
Decision Modeling
12%
Life-years Gained
12%
Comorbidity Index
12%
Decision Model
12%
Relative Cost
12%
Medicine and Dentistry
Lung Cancer
100%
Stereotactic Body Radiation Therapy
100%
Surgery
100%
Cost-Effectiveness Analysis
62%
Health Care Cost
37%
Clinical Stage
37%
Non Small Cell Lung Cancer
37%
Overall Survival
25%
Propensity Score Matching
25%
Hazard Ratio
12%
Arm
12%
Medicare
12%
Lifespan
12%
Cause Specific Survival
12%
Comorbidity
12%
Nursing and Health Professions
Lung Cancer
100%
Stereotactic Body Radiation Therapy
100%
Surgery
100%
Cost Effectiveness Analysis
37%
Non Small Cell Lung Cancer
37%
Overall Survival
25%
Propensity Score
25%
Incremental Cost-Effectiveness Ratio
25%
Hazard Ratio
12%
Medicare
12%
Cause Specific Survival
12%
Comorbidity
12%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Lung Cancer
100%
Overall Survival
66%
Cause Specific Survival
33%
Comorbidity
33%